Autoimmune uveitis: study of treatment therapies

Commodaro, Alessandra Gonçalves; Moraes, Luciana de Deus Vieira de; Tambourgi, Denise Vilarinho; Belfort Jr., Rubens; Sant’Anna, Osvaldo Augusto; Rizzo, Luiz Vicente

doi:10.1590/S1679-45082010RB1416

home Tabla de contenido navigate_before Anterior Actual Siguiente navigate_next

Resumen (Inglés)
Resumen (Portugués)

Texto (Inglés)
Texto (Portugués)

Download PDF (Inglês)
Download PDF (Português)

Resumen (Inglés)
Resumen (Portugués)
Texto (Inglés)
Texto (Portugués)
Download PDF (Inglês) (abre em nova aba)
Download PDF (Português) (abre em nova aba)

Whatsapp
BlueSky
Mastodon
Facebook
Mais

home Tabla de contenido

Whatsapp
BlueSky
Mastodon
Facebook
Mais

Resumen (Inglés)
Resumen (Portugués)

Texto (Inglés)
Texto (Portugués)

Download PDF (Inglês) (abre em nova aba)
Download PDF (Português) (abre em nova aba)

Artigo Original • Einstein (São Paulo) 8 (1) • Jan-Mar 2010 • https://doi.org/10.1590/S1679-45082010RB1416 linkcopy

Autoimmune uveitis: study of treatment therapies

Authorship SCIMAGO INSTITUTIONS RANKINGS

Experimental autoimmune uveitis is an organ-specific T-cell mediated autoimmune disease characterized by inflammation and consequent destruction of the neural retina and adjacent tissues. Inflammation in experimental autoimmune uveitis may be induced in rodents by immunization with retinal antigens, such as interphotoreceptor retinoid-binding protein. We present a review of experimental studies that correlate primary immunobiological functions with this chronic disease and the possible use of molecules for the treatment of autoimmune uveitis.

Keywords:
Uveitis/immunology; Disease models, animal; Antigens/immunology

Authorship

person Alessandra Gonçalves Commodaro

schoolVision Institute of Universidade Federal de São Paulo – UNIFESP, São Paulo (SP), BrazilUniversidade Federal de São Paulo – UNIFESPBrazilSão Paulo, SP, BrazilVision Institute of Universidade Federal de São Paulo – UNIFESP, São Paulo (SP), Brazil

person Luciana de Deus Vieira de Moraes

schoolDepartment of Immunology of Instituto de Ciências Biomédicas da Universidade de São Paulo – USP, São Paulo (SP), BrazilUniversidade de São Paulo – USPBrazilSão Paulo, SP, BrazilDepartment of Immunology of Instituto de Ciências Biomédicas da Universidade de São Paulo – USP, São Paulo (SP), Brazil

person Denise Vilarinho Tambourgi

schoolLaboratory of Immunochemistry of Instituto Butantan – São Paulo (SP), BrazilLaboratory of Immunochemistry of Instituto ButantanBrazilSão Paulo, SP, BrazilLaboratory of Immunochemistry of Instituto Butantan – São Paulo (SP), Brazil

person Rubens Belfort Jr.

schoolInstituto da Visão da Universidade Federal de São Paulo – UNIFESP, São Paulo (SP), BrazilUniversidade Federal de São Paulo – UNIFESPBrazilSão Paulo, SP, BrazilInstituto da Visão da Universidade Federal de São Paulo – UNIFESP, São Paulo (SP), Brazil

person Osvaldo Augusto Sant’Anna

person Luiz Vicente Rizzo

schoolInstituto Israelita de Ensino e Pesquisa Albert Einstein – IIEPAE, São Paulo (SP), BrazilInstituto Israelita de Ensino e Pesquisa Albert Einstein – IIEPAEBrazilSão Paulo, SP, BrazilInstituto Israelita de Ensino e Pesquisa Albert Einstein – IIEPAE, São Paulo (SP), Brazil

Corresponding author: Alessandra Gonçalves Commodaro – Department of Ophthalmology of Federal University of São Paulo – Rua Botucatu, 820 – Vila Clemnetino – CEP 04023-062 – São Paulo (SP), Brazil – Tel.:
30917430 – E-mail:
alecommo@usp.br

None of the authors have any potential financial conflict of interest related to this manuscript.

SCIMAGO INSTITUTIONS RANKINGS

Vision Institute of Universidade Federal de São Paulo – UNIFESP, São Paulo (SP), BrazilUniversidade Federal de São Paulo – UNIFESPBrazilSão Paulo, SP, BrazilVision Institute of Universidade Federal de São Paulo – UNIFESP, São Paulo (SP), Brazil

Department of Immunology of Instituto de Ciências Biomédicas da Universidade de São Paulo – USP, São Paulo (SP), BrazilUniversidade de São Paulo – USPBrazilSão Paulo, SP, BrazilDepartment of Immunology of Instituto de Ciências Biomédicas da Universidade de São Paulo – USP, São Paulo (SP), Brazil

Laboratory of Immunochemistry of Instituto Butantan – São Paulo (SP), BrazilLaboratory of Immunochemistry of Instituto ButantanBrazilSão Paulo, SP, BrazilLaboratory of Immunochemistry of Instituto Butantan – São Paulo (SP), Brazil

Instituto da Visão da Universidade Federal de São Paulo – UNIFESP, São Paulo (SP), BrazilUniversidade Federal de São Paulo – UNIFESPBrazilSão Paulo, SP, BrazilInstituto da Visão da Universidade Federal de São Paulo – UNIFESP, São Paulo (SP), Brazil

Instituto Israelita de Ensino e Pesquisa Albert Einstein – IIEPAE, São Paulo (SP), BrazilInstituto Israelita de Ensino e Pesquisa Albert Einstein – IIEPAEBrazilSão Paulo, SP, BrazilInstituto Israelita de Ensino e Pesquisa Albert Einstein – IIEPAE, São Paulo (SP), Brazil

Figures

Figures (2)

Thumbnail

Figure 1 Treatment with rGal-1 at early or late phases of EAU turns the autoimmune response into non-pathogenic Th2 and Th3 regulatory cytokine profiles. (A-E) Draining lymph nodes cells from rGal-1-treated or control mice were harvested at day 21 and stimulated in vitro with 30 µg/ml IRBP. After 48 hours, IFN-γ (A), IL-5 (B), IL-10 (C), TGF-β (D) and IL-12 (E) levels were determined in culture supernatants by ELISA. Results are expressed as mean pg/ml ± standard deviation. *p < 0.05; ** p < 0.01; *** p < 0.0001.

Thumbnail

Figure 2 LMVp suppresses the clinical signs of actively induced EAU. B10.RIII mice were immunized with 100 µg of IRBP on day 0 and treated with 100 µg i.p. of LMVp 72 hours before immunization. Eyes were collected for histopathology 21 days after immunization. EAU scores were assigned on a scale from 0 to 4, according to the extent of inflammation and tissue damage.

imageFigure 1 Treatment with rGal-1 at early or late phases of EAU turns the autoimmune response into non-pathogenic Th2 and Th3 regulatory cytokine profiles. (A-E) Draining lymph nodes cells from rGal-1-treated or control mice were harvested at day 21 and stimulated in vitro with 30 µg/ml IRBP. After 48 hours, IFN-γ (A), IL-5 (B), IL-10 (C), TGF-β (D) and IL-12 (E) levels were determined in culture supernatants by ELISA. Results are expressed as mean pg/ml ± standard deviation. p < 0.05; p < 0.01; p < 0.0001. open_in_new

Source: Toscano MA et al.(³⁵)

imageFigure 2 LMVp suppresses the clinical signs of actively induced EAU. B10.RIII mice were immunized with 100 µg of IRBP on day 0 and treated with 100 µg i.p. of LMVp 72 hours before immunization. Eyes were collected for histopathology 21 days after immunization. EAU scores were assigned on a scale from 0 to 4, according to the extent of inflammation and tissue damage. open_in_new

Source: Commodaro et al.(⁴⁶)

How to cite

linkcopy

Ferramentas do artigo

PDFs
Métricas
Figuras e tabelas
Versiones y traducciones
Como citar este artículo
Artículos relacionados

location_on

Instituto Israelita de Ensino e Pesquisa Albert Einstein Avenida Albert Einstein, 627/701 , 05651-901 São Paulo - SP, Tel.: (55 11) 2151 0904 - São Paulo - SP - Brazil
E-mail: revista@einstein.br

rss_feed Acompañe los números de esta revista en su lector de RSS

Versão para download de PDF

PDF

Inglés
Portugués

Versões e tradução automática

Escolha a versão original do texto ou utilize um serviço de tradução automática.

Versão original do texto

English
Português

Tradução automática

Google Translator (abre serviço externo de tradução)
Microsoft Translator (abre serviço externo de tradução)

Como citar

Escolha um formato para exportar ou selecione um estilo de citação. O conteúdo abaixo pode ser atualizado após a seleção.

Baixar em RIS

Baixar em BIBTEX

Outros formatos de citação e exportação: